Evidence is mounting supporting the use of self-collected specimens for HPV and other infectious disease testing in both the developing and developed world.
The partnership is the second this year aimed at widening distribution of the GeneXpert to moderately complex labs in the US.
The upgraded test includes new gene targets for methicillin resistance, and provides room-temperature storage and validation on multiple swab types.
The test is the 20th US-IVD molecular diagnostic on the GeneXpert menu — Cepheid also recently announced that it has now placed its 10,000 systems globally.
The firm attributed the growth to record reagent revenues and GeneXpert system placements.
Executives from several life science research tool and diagnostic firms provided conference attendees with updates on their businesses.
Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.
The firm reported preliminary financial results in line with previous guidance and the average Wall Street estimate.
The firm signed a memorandum of understanding with the agency and is expected to detail the terms of the cooperation in a subsequent collaborative agreement.
The agreement extends Cepheid's reach beyond the hospital lab environment into the moderately complex lab space.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.